Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDFate Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 6 | -$0.47 | -$0.47 | -$0.47 |
| Q2 2024 | 6 | -$0.46 | -$0.46 | -$0.46 |
| Q3 2024 | 4 | -$0.42 | -$0.42 | -$0.42 |
| Q4 2024 | 11 | -$0.48 | -$0.39 | -$0.44 |
| Q1 2025 | 6 | -$0.49 | -$0.39 | -$0.45 |
| Q2 2025 | 5 | -$0.43 | -$0.43 | -$0.43 |
| Q3 2025 | 5 | -$0.44 | -$0.44 | -$0.44 |
| Q4 2025 | 5 | -$0.45 | -$0.45 | -$0.45 |
| Q1 2026 | 2 | -$0.38 | -$0.38 | -$0.38 |
| Q2 2026 | 2 | -$0.38 | -$0.38 | -$0.38 |
| Q3 2026 | 2 | -$0.38 | -$0.38 | -$0.38 |
| Q4 2026 | 2 | -$0.38 | -$0.38 | -$0.38 |
Fate Therapeutics, Inc. Earnings Date And Information
Fate Therapeutics, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.4 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.02. The company had revenue of 3.07 M for the quarter and had revenue of 63.53 M for the year. Fate Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.64 diluted earnings per share) and currently has a price-to-earnings ratio of -1.06. Fate Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based on prior year's report dates.
Fate Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.42 | -$0.40 | 0.02 | $1.24 M | $3.07 M |
| 08/13/2024 | Q2 2024 | -$0.47 | -$0.33 | 0.14 | $1.33 M | $6.77 M |
| 05/09/2024 | Q1 2024 | -$0.47 | -$0.47 | 0 | $1.93 M | |
| 02/26/2024 | Q4 2023 | -$0.57 | -$0.45 | 0.12 | $1.68 M | |
| 11/08/2023 | Q3 2023 | -$0.59 | -$0.46 | 0.13 | $1.55 M | $1.94 M |
| 08/08/2023 | Q2 2023 | -$0.58 | -$0.54 | 0.04 | $5.41 M | $933,000 |
| 05/03/2023 | Q1 2023 | -$0.55 | -$0.09 | 0.46 | $58.98 M | |
| 02/28/2023 | Q4 2022 | -$0.86 | -$0.50 | 0.36 | $44.36 M | |
| 11/03/2022 | Q3 2022 | -$0.93 | -$0.83 | 0.1 | $15.28 M | $14.98 M |
| 08/03/2022 | Q2 2022 | -$0.86 | -$0.79 | 0.07 | $12.54 M | $18.55 M |
| 05/04/2022 | Q1 2022 | -$0.78 | -$0.59 | 0.19 | $18.41 M | |
| 02/28/2022 | Q4 2021 | -$0.68 | -$0.72 | -0.04 | $17.07 M | |
| 11/04/2021 | Q3 2021 | -$0.58 | -$0.45 | 0.13 | $8.10 M | $14.23 M |
| 08/04/2021 | Q2 2021 | -$0.52 | -$0.58 | -0.06 | $6.75 M | $13.41 M |
| 05/05/2021 | Q1 2021 | -$0.42 | -$0.48 | -0.06 | $11.14 M | |
| 02/24/2021 | Q4 2020 | -$0.38 | -$0.61 | -0.23 | $15.90 M | |
| 11/05/2020 | Q3 2020 | -$0.29 | -$0.68 | -0.39 | $7.26 M | $7.56 M |
| 08/05/2020 | Q2 2020 | -$0.20 | -$0.35 | -0.15 | $13.97 M | $5.47 M |
| 05/11/2020 | Q1 2020 | -$0.38 | -$0.44 | -0.06 | $2.52 M | |
| 03/02/2020 | Q4 2019 | -$0.39 | -$0.37 | 0.02 | $2.80 M |
Fate Therapeutics, Inc. Earnings: FAQ's
When is Fate Therapeutics, Inc.'s earnings date?
Fate Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates.
Did Fate Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Fate Therapeutics, Inc. (:FATE) reported $-0.4 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.02.
How can I listen to Fate Therapeutics, Inc.'s earnings conference
call?
The conference call for Fate Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Fate Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Fate Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Fate Therapeutics, Inc. generate each year?
Fate Therapeutics, Inc. (:FATE) has a recorded annual revenue of $63.53 M.
How much profit does Fate Therapeutics, Inc. generate each year?
Fate Therapeutics, Inc. (:FATE) has a recorded net income of $63.53 M. Fate Therapeutics, Inc. has generated $-1.64 earnings per share over the last four quarters.
What is Fate Therapeutics, Inc.'s price-to-earnings ratio?
Fate Therapeutics, Inc. (:FATE) has a price-to-earnings ratio of -1.06 and price/earnings-to-growth ratio is -0.3.